Levetiracetam …

K K Jain MD†

Neuropharmacology & Neurotherapeutics

Updated 03.01.2021
Released 01.20.2000
Expires For CME 03.01.2024

Levetiracetam

Author: K K Jain MD†

See Contributor Disclosures

Levetiracetam

In This Article

Quick Link

Introduction

Historical note and terminology

Levetiracetam is a pyrrolidone derivative and not related to any of the antiepileptic drugs currently in use. It has been approved by the Food and Drug Administration in the United States and in the European Union and various other countries. Although levetiracetam is more expensive than traditional antiepileptic drugs, its cost is comparable to that of newer antiepileptic drugs.

Pharmacology

The chemical name of levetiracetam is (S)-alpha-ethyl-2-oxo-pyrrolidine acetamide.

Pharmacodynamics. The exact mechanism of action of levetiracetam is not known. Levetiracetam binds selectively to a synaptic vesicle protein (SV2) involved with presynaptic neurotransmitter release. Glioma patients who respond well to treatment with levetiracetam for control of seizures have significantly stronger SV2A expression as demonstrated by immunohistochemical examination of tumor as well as in peritumoral tissue than patients who did not show such a response (05).

Unlike all other antiepileptic agents currently available, levetiracetam shows no activity in 2 standard acute seizure models used to screen new compounds for evidence of seizure control (the maximal electroshock model and the pentylenetetrazol seizure model). Paradoxically, however, levetiracetam is highly effective in animal models of chronic epilepsy, with broad spectrum activity in models for partial and generalized epilepsy. In vivo studies show that inhibitory CNS effects of levetiracetam are due to ion channel modulation.

Pharmacokinetics. Important points of pharmacokinetics of levetiracetam are as follows:

	• It is completely absorbed after oral administration and has predictable, linear pharmacokinetics. The extent of absorption is unaffected by food. Two-thirds of the dose is excreted unchanged by the kidneys.
	• With twice-daily dosing, steady state is reached after 48 hours.
	• It is less than 10% protein-bound, and metabolism is not dependent on hepatic cytochrome P450.
	• Plasma half-life is approximately 6 to 8 hours, but this is increased in patients with renal impairment.
	• Both serum and cerebrospinal fluid levetiracetam concentrations rise essentially linearly and dose-dependently, suggesting that transport across the blood-brain barrier is not rate-limiting. Half-life in the central nervous system is longer than plasma half-life.
	• Serum samples separated immediately from withdrawn blood are recommended for therapeutic monitoring of levetiracetam level, as B-esterases in whole blood can metabolize levetiracetam and cause spuriously low concentrations.

Therapeutic drug monitoring. In 1 study, blood levels of levetiracetam ranging between 20 and 40mg/L were helpful in the management of seizures, and impaired efficacy of the drug with drop in therapeutic levels were explained by interactions with other antiepileptic comedications (33). Another study concluded that routine therapeutic drug monitoring is not necessary but suggested the need for further investigations in special patient populations (30).

A simple, fast, and cost-effective method for the determination of levetiracetam in plasma/serum of patients using high performance liquid chromatography with ultraviolet detection requires minimal sample preparation and is suitable for daily routine use in therapeutic drug monitoring (08). A study has demonstrated transdermal extraction of measurable amounts of levetiracetam across the pig ear skin by reverse iontophoresis for noninvasive therapeutic drug monitoring (10).

Methods of administration. Although mostly used as oral preparation, intravenous formulations are also available. Continuous subcutaneous levetiracetam infusion has been used in the management of seizures at the end of life (36). An open study has shown that an extended-release formulation of levetiracetam was well tolerated when administered as long-term monotherapy or in combination with other AEDs in patients with inadequately controlled partial onset epilepsy (02). A controlled clinical trial has shown that extended-release and immediate-release formulations of levetiracetam are equivalent in reducing the frequency of partial-onset seizures and have a similar tolerability as an adjunctive treatment for adult patients with uncontrolled epilepsy (37).

Clinical trials

The first clinical trials on which approval of levetiracetam was based, were conducted between 1995 and 2000. Levetiracetam has been investigated as add-on therapy for partial seizures in 3 placebo-controlled phase 3 studies. In these studies, 904 patients, in both the United States and Europe, had experienced refractory partial onset seizures with or without secondary generalization for at least 2 years and had taken 2 or more standard antiepileptic drugs. The measure of effectiveness included the responder rate (incidence of patients with a greater than 50% reduction from baseline in partial onset seizure frequency for the entire treatment period). The responder rate was statistically significantly greater in patients taking levetiracetam 1000 mg/day, 2000 mg/day, or 3000 mg/day as compared to placebo within each study. The responder rate was between 22.8% and 33% on 1000 mg, 31.6% on 2000 mg, and between 39.4% and 42.1% on 3000 mg, as compared to placebo rates of 10.9% to 16.7% (13). A few selected clinical trials of levetiracetam during the previous decade are cited in this article.

A randomized, single-blind, placebo-controlled study showed that levetiracetam administered by intravenous infusion was well tolerated in healthy subjects and the pharmacokinetic profile was consistent with orally administered levetiracetam.

In a prospective add-on study of children with refractory epilepsy, levetiracetam was effective in 54.3% of patients, decreasing seizure frequency to at least 50% of baseline frequency (34).

In Asia SKATE II study, levetiracetam was well tolerated and efficacious as adjunctive therapy for partial epilepsy in Asian populations (16).

A Cochrane review of 11 clinical trials concluded that it is reasonable to continue the use of levetiracetam in both adults and children with drug-resistant focal epilepsy, but longer-term effects of monotherapy on generalized seizures cannot be determined from these results (22).

An open phase II trial of levetiracetam following acute head injury in children who were at risk for developing posttraumatic epilepsy showed that only 1 child among 40 participants developed this complication (24). These results support the conduct of a prospective phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy.

A metaanalysis of randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types showed efficacy in reducing the frequency of seizures in partial as well as idiopathic generalized epilepsy in both adults and children, with good tolerance (09).

A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults showed that the drug was well tolerated in this population and had pharmacokinetic advantages (28).

Indications

Levetiracetam is indicated as an adjunctive therapy in the treatment of partial seizures with or without secondary generalization in adults.

In 2006, the European Commission approved the use of levetiracetam as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age or older with juvenile myoclonic epilepsy. In 2007, the European Commission approved a new indication for levetiracetam as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy.

Off-label uses

Phenytoin is the current standard of care for second-line treatment of pediatric convulsive status epilepticus after failure of first-line benzodiazepines, but is only effective in 60% of cases and is associated with considerable adverse effects. Intravenous levetiracetam is used in patients with status epilepticus who do not respond to intravenous benzodiazepines. A review of case series and prospective studies shows the success rate of levetiracetam for termination of status epilepticus to be 55 % to 59.4 %, but its use in the treatment of generalized convulsive status epilepticus is still questionable because of delayed effect (25). Results of 2 randomized clinical trials show that levetiracetam is no better than phenytoin in terminating status epilepticus in children (04; 19). However, the relative safety and comparative ease of administration of levetiracetam suggest that it could be an appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of pediatric convulsive status epilepticus.

Other reported uses of levetiracetam include the following:

	• Management of acute mania
	• Treatment of paroxysmal kinesigenic choreoathetosis
	• Levetiracetam reduces phasic spasticity but not tonic spasticity in multiple sclerosis.
	• A double-blind, randomized controlled trial did not show efficacy of levetiracetam in generalized social anxiety disorder (32).
	• Cluster headaches
	• Pediatric migraine
	• For the treatment of levodopa-induced dyskinesias in Parkinson disease (31)
	• Tourette syndrome
	• Tardive dyskinesia
	• Meige syndrome
	• As monotherapy in Alzheimer patients with late-onset seizures
	• Adjunctive treatment for patients with anxiety disorders
	• As add-on therapy in severe myoclonic epilepsy of infancy
	• Treatment of lumbar radiculopathy
	• Late-onset myoclonic epilepsy in Down syndrome (27)
	• Most of the placebo-controlled clinical trials of levetiracetam for the treatment of neuropathic pain have not shown any benefit (06).
	• In a mouse model of Alzheimer disease, chronic treatment with levetiracetam was shown to reverse behavioral abnormalities, synaptic dysfunction, and deficits in learning and memory (26).
	• Although open studies suggested usefulness of levetiracetam in alcohol withdrawal, a randomized-controlled trial showed it was ineffective (17).
	• A multicenter, retrospective, open-label study has shown that levetiracetam is effective for electrical status epilepticus during sleep (01).
	• Levetiracetam has been used for the treatment of epileptic seizures after liver transplantation (18).
	• Levetiracetam has been used to increase survival in patients with glioblastoma multiforme receiving temozolomide-based chemotherapy. Results of a combined analysis of levetiracetam use at the start of chemoradiotherapy with temozolomide in 4 contemporary, randomized clinical trials of patients with glioblastoma did not show any survival benefits, and use of levetiracetam is not justified for reasons other than seizure control (12).
	• Levetiracetam was used for successful control of clonic seizures in an infant with epileptic encephalopathy due to mutation of syntaxin binding protein 1 (STXBP1) gene after other antiepileptic drugs had failed (07). Levetiracetam acts by modulating the synaptic vesicle release, which is affected by STXBP1 mutation.
	• A retrospective study has shown that levetiracetam is effective in treatment of seizures due to neonatal hypoxic ischemic encephalopathy (35).

Special considerations

Pediatric. Levetiracetam is still in clinical studies for pediatric epilepsies. The pharmacokinetics of levetiracetam in children are like those in adults, except with a higher nonrenal clearance (approximately 40% greater), which may explain the need for higher doses in children compared to adults. Levetiracetam treatment is safe and effective in children younger than 2 years of age with various types of epilepsy. A randomized, blinded, phase IIb trial of efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment for neonatal seizures of any cause showed that phenobarbital was more effective than levetiracetam, although higher rates of adverse effects were seen with phenobarbital treatment (Sharpe et al 2020). Because an improvement in efficacy of levetiracetam was achieved with dose escalation, higher-dose studies of levetiracetam are warranted.

Geriatric. Dosage should be adapted in cases of renal insufficiency. In patients with moderate to severe renal dysfunction, the dose of levetiracetam should be reduced by 50%, still given twice daily.

Pregnancy. A study based on registers of epilepsy and pregnancy in UK and Ireland showed a low risk for major congenital malformations with levetiracetam monotherapy as compared to its use as a part of polytherapy regimen (21). Another retrospective study showed that the use of levetiracetam as monotherapy during pregnancy has the same risk level for fetal malformations as the group who never used antiepileptic drugs and that the risk increased when it was used as a part of polytherapy (15). No controlled studies have been performed in pregnant women. Because of the potential risk to the fetus during pregnancy, levetiracetam should be used only if the benefits outweigh the risks.

Anesthesia. No special precautions are listed.

References

01: Chen XQ, Zhang WN, Yang ZX, et al. Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. Pediatr Neurol 2014;50(3):243-9. PMID 24316167
02: Chung S, Ceja H, Gawłowicz J, McShea C, Schiemann J, Lu S. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study. Epilepsy Res 2016;120:7-12. PMID 26716580
03: Cvetkovska E, Kuzmanovski I, Babunovska M, Boshkovski B, Aleksovska K, Trencevska GK. Levetiracetam-induced seizure aggravation in patients with focal cortical dysplasia. Clin Neuropharmacol 2018;41(6):218-21. PMID 30234559
04: Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019;393(10186):2135-45. PMID 31005386
05: de Groot M, Aronica E, Heimans JJ, Reijneveld JC. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology 2011;77(6):532-9. PMID 21795655
06: del Pozo E, Pereira-Pérez E, González-Contreras LG. The effectiveness of levetiracetam in the treatment of neuropathic pain. Rev Neurol 2011;53(2):65-72. PMID 21720975
07: Dilena R, Striano P, Traverso M, et al. Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation. Brain Dev 2016;38(1):128-31. PMID 26212315
08: Engelbrecht L, Grobler CJ, Rheeders M. A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy. Biomed Chromatogr 2017;31(10). PMID 28294369
09: Fang Y, Wu X, Xu L, et al. Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types. J Clin Neurosci 2014;21(1):55-62. PMID 24231559
10: Giri TK, Ghosh B, Bose P, Saha S, Sarkar A. Extraction of levetiracetam for therapeutic drug monitoring by transdermal reverse iontophoresis. Eur J Pharm Sci 2019;128:54-60. PMID 30468869
11: Gupta M. Levetiracetam-induced leukocytoclastic vasculitis. Indian J Pharmacol 2017;49(1):124-6. PMID 28458437
12: Happold C, Gorlia T, Chinot O, et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 2016;34(7):731-9. PMID 26786929
13: Jain KK. An assessment of levetiracetam as an anti-epileptic drug. Expert Opin Investig Drugs 2000;9:1611-24. PMID 11060713
14: Kang BS, Moon HJ, Kim YS, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disord 2013;15(3):302-10. PMID 23981665
15: Koc G, Keskin Guler S, Karadas O, Yoldas T, Gokcil Z. Fetal safety of levetiracetam use during pregnancy. Acta Neurol Belg 2018;118(3):503-8.** PMID 30056483
16: Kwan P, Lim SH, Chinvarun Y, et al. Efficacy and safety of levetiracetam as adjunctive therapy in adult patients with uncontrolled partial epilepsy: the Asia SKATE II Study. Epilepsy Behav 2010;18(1-2):100-5. PMID 20462804
17: Le Strat Y. Levetiracetam in the treatment of alcohol dependence: toward the end of the story. Alcohol Clin Exp Res 2012;36(8):1309-10. PMID 22823576
18: Lin CH, Chen CL, Lin TK, Chen NC, Tsai MH, Chuang YC. Levetiracetam in the treatment of epileptic seizures after liver transplantation. Medicine (Baltimore) 2015;94(38):e1350. PMID 26402799
19: Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393(10186):2125-34. PMID 31005385
20: Makke Y, Hmaimess G, Nasreddine W, Fawaz A, Beydoun A. Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC Pediatr 2015;15:6. PMID 25884503
21: Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80(4):400-5. PMID 23303847
22: Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev 2012;9:CD001901. PMID 22972056
23: Muramatsu K, Sawaura N, Ogata T, et al. Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy. Brain Dev 2017;39(3):231-5. PMID 27745925
24: Pearl PL, McCarter R, McGavin CL, et al. Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy. Epilepsia 2013;54(9):e135-7. PMID 23876024
25: Rösche J, Dudek M, Teleki A, Godau J, Bösel J. Levetiracetam for treatment of status epilepticus - an update. Fortschr Neurol Psychiatr 2019;87(6):357-63. [Article in German] PMID 31261415
26: Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 2012;109(42):E2895-903. PMID 22869752
27: Sangani M, Shahid A, Amina S, Koubeissi M. Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. Epileptic Disord 2010;12(2):151-4. PMID 20483713
28: Schoenberg MR, Rum RS, Osborn KE, Werz MA. A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. Epilepsia 2017;58(9):1566-74. PMID 28731266
29: Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics 2020;145(6):e20193182. Erratum in: Pediatrics 2021;147(1). PMID 32385134 **
30: Sourbron J, Chan H, Wammes-van der Heijden EA, et al. Review on the relevance of therapeutic drug monitoring of levetiracetam. Seizure 2018;62:131-5. PMID 30237016
31: Stathis P, Konitsiotis S, Tagaris G, Peterson D; VALID-PD Study Group. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2011;26(2):264-70. PMID 21412833
32: Stein MB, Ravindran LN, Simon NM, et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry 2010;71(5):627-31. PMID 20021997
33: Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure 2014;23(5):371-6. PMID 24630809
34: Tonekaboni SH, Ghazavi M, Karimzadeh P, Mahvelati F, Ghofrani M. Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial. Epilepsy Res 2010;90(3):273-7. PMID 20619606
35: Venkatesan C, Young S, Schapiro M, Thomas C. Levetiracetam for the treatment of seizures in neonatal hypoxic ischemic encephalopathy. J Child Neurol 2017;32(2):210-4. PMID 27872177
36: Wells GH, Mason LD, Foreman E, Chambers J. Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. Age Ageing 2016;45(2):321-2. PMID 26744359
37: Wu T, Lim SN, Tsai JJ, et al. A randomized, double-blind, double-dummy, multicenter trial comparing the efficacy and safety of extended- and immediate-release levetiracetam in people with partial epilepsy. Seizure 2018;62:84-90. PMID 30308428

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Levetiracetam

Other Pertinent Drugs

piracetam

Also Relevant

Absence status epilepticus
Anticonvulsants
Childhood absence epilepsy
Epilepsy
Eyelid myoclonia with and without absences
- Idiopathic photosensitive occipital lobe epilepsy
- Juvenile myoclonic epilepsy
- Migraine
- Multiple sclerosis
- Myoclonic seizures
- Myoclonus
- Neuropharmacology
- Paroxysmal dyskinesias
- Pharmacological treatment of epilepsy in adolescents and adults
- Tardive dyskinesia
- Tourette syndrome
- Typical absence seizures
- Visual-sensitive epilepsies

Levetiracetam …

Levetiracetam

Introduction

Historical note and terminology

Pharmacology

Clinical trials

Indications

Off-label uses

Contraindications

Goals and duration of treatment

Dosing

Special considerations

Interactions

Adverse effects

References

Contributors

Author

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Alcohol withdrawal seizures

Acupuncture

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

	• Mentally retarded patients with therapy-resistant seizures where high doses of levetiracetam are used.
	• Myoclonic astatic epilepsy (20).
	• Levetiracetam may possibly induce seizure exacerbation in a subset of patients with focal cortical dysplasia–related epilepsy (03).

Levetiracetam

Introduction

Historical note and terminology

Pharmacology

Clinical trials

Indications

Off-label uses

Contraindications

Goals and duration of treatment

Dosing

Special considerations

Interactions

Adverse effects

References

Contributors

Author

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Alcohol withdrawal seizures

Acupuncture

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

This is an article preview.
Start a Free Account
to access the full version.